UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________
FORM 8-A
________________________
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
IMPRIMIS PHARMACEUTICALS, INC
(Exact name of registrant as specified in its charter)
|
Delaware
|
45-0567010
|
|
|
(State of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
437 S. Hwy 101, Suite 209
Solana Beach, California
|
92075
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title of each class
to be so registered
|
Name of each exchange on which
each class is to be registered
|
|
|
Common Stock,
$0.001 par value per share
|
The NASDAQ Stock Market LLC
|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. þ
|
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. p
|
Securities Act registration statement file number to which this form relates: File No. 333-182846
Securities to be registered pursuant to Section 12(g) of the Act: None
Item 1.Description of Registrant’s Securities to be Registered.
Imprimis Pharmaceuticals, Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, par value $0.001 per share, to be registered hereunder that is contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-182846), as originally filed with the Securities and Exchange Commission (the “Commission”) on July 25, 2012 and as subsequently amended (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.
Item 2.Exhibits.
Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed herewith because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
2
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMPRIMIS PHARMACEUTICALS, INC. | |||
|
Date: February 7, 2013
|
By:
|
/s/ Andrew R. Boll | |
| Name: | Andrew R. Boll | ||
| Title: | Vice-President of Accounting and Public Reporting | ||
3